{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Bello D"],"funding":["NIDA NIH HHS","NIMH NIH HHS","NIAAA NIH HHS"],"pubmed_abstract":["Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco (\"co-use\") is rising in the general population but has not been studied in psychosis. Given the devastating consequences of cannabis and tobacco use, it is critical to understand how their co-use affects psychiatric symptoms and the development of psychosis. We used the North American Prodrome Longitudinal Study 2, a multi-site prospective study of individuals at clinical high risk for psychosis (CHR) and healthy controls, to examine baseline differences in psychiatric symptoms and conversion to psychosis across substance groups: 1) CHR tobacco use, 2) CHR cannabis use, 3) CHR co-use, 4) CHR non-tobacco or cannabi"],"journal":["medRxiv : the preprint server for health sciences"],"pagination":["2025.09.19.25336202"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12458528"],"repository":["biostudies-literature"],"pubmed_title":["Cannabis and Tobacco Co-Use Predicts Psychosis in Clinical High Risk Cohorts."],"pmcid":["PMC12458528"],"funding_grant_id":["U01 MH082022","T32 AA013525","U01 MH066069","U01 MH066134","U01 MH081928","K23 DA059690","P50 MH066286","R01 MH116170","R01 MH076989","U01 MH081902","U01 MH081988","U01 MH081857","U01 MH081944"],"pubmed_authors":["Mathalon DH","Addington J","Bearden CE","Walker EF","Brady RO","Rabin RA","Ward HB","Carrion RE","Perkins DO","Bello D","Blyth SH","Woods S","Stone WS","Cadenhead K","Cornblatt B","Keshavan M","Tsuang MT","Seidman L","Cannon TD"],"additional_accession":[]},"is_claimable":false,"name":"Cannabis and Tobacco Co-Use Predicts Psychosis in Clinical High Risk Cohorts.","description":"Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco (\"co-use\") is rising in the general population but has not been studied in psychosis. Given the devastating consequences of cannabis and tobacco use, it is critical to understand how their co-use affects psychiatric symptoms and the development of psychosis. We used the North American Prodrome Longitudinal Study 2, a multi-site prospective study of individuals at clinical high risk for psychosis (CHR) and healthy controls, to examine baseline differences in psychiatric symptoms and conversion to psychosis across substance groups: 1) CHR tobacco use, 2) CHR cannabis use, 3) CHR co-use, 4) CHR non-tobacco or cannabi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-03T03:21:43.837Z","creation":"2026-05-03T03:12:25.339Z"},"accession":"S-EPMC12458528","cross_references":{"pubmed":["41001470"],"doi":["10.1101/2025.09.19.25336202"]}}